US87650L1035
US87650L1035
Tarsus Pharmaceuticals, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±58.4% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).
Beta (Market Relation)
0.45x
DefensiveVolatility (5Y p.a.)
58.4% p.a.
5-Year HorizonMax Drawdown (5Y)
-62.7%
5-Year HorizonSharpe Ratio
0.37
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +3.5% |
| 3 Years | 53.2% | -45.1% | 1.16 | +64.2% |
| 5 Years | 58.4% | -62.7% | 0.37 | +24.1% |
| 10 Years | — | — | — | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (58.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -62.7% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
8 ISS Score: 8 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
7.90